Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MP0317 |
| Synonyms | |
| Therapy Description |
MP0317 consists of four covalently linked designed ankyrin repeat protein (DARPin) domains that bind FAP, CD40, and human serum albumin, which activates CD40 signaling and potentially increases antitumor immune activity within the tumor microenvironment (PMID: 42067655). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MP0317 | MP-0317|MP 0317 | MP0317 consists of four covalently linked designed ankyrin repeat protein (DARPin) domains that bind FAP, CD40, and human serum albumin, which activates CD40 signaling and potentially increases antitumor immune activity within the tumor microenvironment (PMID: 42067655). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05098405 | Phase I | MP0317 | First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors | Terminated | NLD | FRA | 0 |